Low Molecular Weight Proteomic Information Distinguishes Metastatic from Benign Pheochromocytoma
Metastatic lesions occur in up to 36% of patients with pheochromocytoma. Currently there is no way to reliably detect or predict which patients are at risk for metastatic pheochromocytoma. Thus, the discovery of biomarkers that could distinguish patients with benign disease from those with metastatic disease would be of great clinical value. Using surface-enhanced laser desorption ionization protein chips combined with high-resolution mass spectrometry, we tested the hypothesis that pheochromocytoma pathologic states can be reflected as biomarker information within the low molecular weight (LMW) region of the serum proteome. LMW protein profiles were generated from the serum of 67 pheochromocytoma patients from four institutions and analyzed by two different bioinformatics approaches employing pattern recognition algorithms to determine if the LMW component of the circulatory proteome contains potentially useful discriminatory information. Both approaches were able to identify combinations of LMW molecules which could distinguish all metastatic from all benign pheochromocytomas in a separate blinded validation set. In conclusion, for this study set low molecular mass biomarker information correlated with pheochromocytoma pathologic state using blinded validation. If confirmed in larger validation studies, efforts to identify the underlying diagnostic molecules by sequencing would be warranted. In the future, measurement of these biomarkers could be potentially used to improve the ability to identify patients with metastatic disease.
Adolescent, adrenal gland neoplasms, biomarkers, tumor, child, Diagnosis, differential, molecular weight, neoplasm metastasis, neoplasm proteins, pheochromocytoma, proteome, proteomics
Brouwers, F. M.; Petricoin, E. F.; Ksinantova, L.; Breza, J.; Rajapakse, V.; Ross, S.; Johann, D.; Mannelli, M.; Shulkin, B. L.; Veenstra, Timothy D.; and et al, "Low Molecular Weight Proteomic Information Distinguishes Metastatic from Benign Pheochromocytoma" (2005). Pharmaceutical Sciences Faculty Publications. 427.